Damien Keogh PhD

Damien is an Entrepreneur-in-Residence at ESCO Ventures and adds scientific experience to the ESCO Ventures team. As an EIR Damien’s primary focus is on creating investable drug discovery platform concepts that ESCO Ventures can seed. Damien founded Maiden Therapeutics at ESCO Ventures in 2018, which is currently operational at the Esco Ventures X incubator laboratory.

Damien is a Molecular Microbiologist by training (Ph.D. 2008 Dublin, Ireland). Bristol-Myers Squibb Ltd sponsored his first postdoctoral research work, and Damien earned research commercialization experience through the spin-out phase of a glycoselective separation technology company. He also brings significant experience as a Faculty lecturer, managing innovative research projects, and integrating multidisciplinary teams. He has been embedded in the Singapore Life Science scene since 2012, primarily at the Singapore Centre for Environmental Life Science Engineering (SCELSE).